XML 57 R41.htm IDEA: XBRL DOCUMENT v3.25.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2025
Income Taxes [Abstract]  
Schedule of Theoretical Income Tax and Effective Income Tax

The following table presents the reconciliation between the Company’s theoretical income tax and effective income tax for the year ended December 31, 2025 after the adoption of ASU 2023-09:

 

   2025   2024 
   $   %   $   % 
U.S. federal Statutory tax rate   (7,600)   (21)   (3,720)   (21)
                     
Foreign tax effects:                    
Israel                    
Statutory tax rate difference   (481)   (1.33)   (428)   (2.42)
Change in valuation allowance   5,336    14.74    4,190    23.65 
Stock-based compensation   428    1.18    329    1.86 
Other nondeductible items   (18)   (0.05)   (18)   (0.1)
                     
Nontaxable or Nondeductible items:                    
Stock-based compensation   
-
    
-
    154    0.87 
Gain from early lease termination   (819)   (2.26)   
-
    
-
 
Change in valuation allowance   3,440    9.5    (924)   (5.22)
Other adjustments   (279)   (0.76)   430    2.43 
Total Effective Tax Rate   7    0.02    13    0.07 
Schedule of Loss Before Taxes on Income

Loss before taxes on income, consists of the following:

 

   Year ended
December 31,
 
   2025   2024 
         
Domestic - United States   12,145    (3,511)
Foreign - Israel   24,047    21,225 
    36,192    17,714 
Schedule of Net Deferred Tax Assets

Net deferred tax assets as of December 31, 2025 and 2024 consisted of the following:

 

   As of December 31, 
   2025   2024 
         
Deferred tax assets:        
Net operating loss carryforwards   51,579    42,454 
Research and development expenses, net   8,737    10,898 
Lease liability   
-
    785 
Research and development tax credits (*)   601    601 
Fixed assets   310    
-
 
IPR&D - Intangible Asset   2,192    
-
 
Other   1,038    838 
Total deferred tax assets   64,457    55,576 
Deferred tax liabilities:          
Right of use assets   
-
    (847)
IPR&D - Intangible Asset   
-
    (127)
Private Placement Warrants   (6,840)   (5,571)
Fixed assets   
-
    (190)
Total deferred tax liabilities   (6,840)   (6,735)
Valuation allowance   (57,617)   (48,841)
Net deferred tax assets   
-
    
-
 

 

  (*) Research and development tax credits will begin to expire in 2038.